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Abstract
Introduction. HPV vaccination is recommended in many countries, including Italy, for girls in their twelfth year of age. In some
countries, the goal of vaccination coverage has not been reached, and extension to boys has thus been debated.
Objective. Aim of this study is to perform a systematic review of pharmaco-economic studies considering the extension of HPV
vaccination to boys.
Methods. An electronic literature search was performed on Pubmed to identify studies published from 2005 to 2015 in Eng-
lish and Italian. Four search strategies were used, including the terms «HPV», «boys», «vaccination», «economic evaluation»,
«cost effectiveness», and «epidemiological impact». Screening of titles, abstracts, and full texts was conducted, and economi-
cal evaluation of the extension of HPV vaccination to males was considered a criteria of inclusion. A total of 289 articles were
identified. Only 15 articles were finally considered pertinent.
Results. The extension of HPV vaccination to boys was cost-effective or potentially cost-effective in 53% and 7% of the studies,
respectively. Six studies did not positively evaluate the implementation of this intervention. However, taking into account both the
new two-dose vaccination schedule available for all subjects ≤13 years, and the dramatic reduction in the price of vaccines in the
last few years, the advantages of universal vaccination are more consistent.
Conclusion. The extension of HPV vaccination to boys is therefore foreseen to become increasingly implemented in the near
future.
(Epidemiol Prev 2015; 39(4) Suppl 1: 51-58)
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Riassunto
Introduzione. La vaccinazione anti-HPV è raccomandata in molti Paesi, tra cui l’Italia, alle ragazze nel dodicesimo anno di vita.
In diverse nazioni l’obiettivo di copertura vaccinale non è stato raggiunto e l’estensione ai maschi è in discussione.
Obiettivo. Scopo dello studio è stato quello di effettuare una revisione sistematica degli studi farmaco-economici che valuta-
no l’estensione della vaccinazione anti-HPV ai maschi.
Metodi. E’ stata condotta una ricerca sugli studi pubblicati dal 2005 al 2015 in inglese e italiano su Pubmed, utilizzando 4 strin-
ghe di ricerca che includevano i termini «HPV», «boys», «vaccination», «economic evaluation», «cost effectiveness», «epidemiological
impact». Gli articoli sono stati inizialmente selezionati se nel titolo, nell’abstract e nel testo esaminavano a livello economico l’esten-
sione della vaccinazione anti-HPV ai maschi. Sono stati individuati 289 articoli: solo 15 sono stati ritenuti infine pertinenti.
Risultati. L’estensione della vaccinazione anti-HPV ai maschi risulta costo-efficace o potenzialmente costo-efficace rispettivamente
nel 53% e nel 7% degli studi. Sei articoli, in base alle loro assunzioni, non valutano positivamente l’implementazione di tale in-
tervento. Tuttavia, considerando la nuova schedula vaccinale a due dosi disponibile per tutti i soggetti di età ≤13 anni e la no-
tevole riduzione del prezzo del vaccino intervenuta negli ultimi anni, si rende necessario aggiornare tali valutazioni utilizzando i
nuovi dati di input.
Conclusioni. L’estensione della vaccinazione anti-HPV anche ai maschi sembra essere un intervento destinato a sempre più am-
pia applicazione nel prossimo futuro.
(Epidemiol Prev 2015; 39(4) Suppl 1: 51-58)
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INTRODUCTION
Infection due to high-riskHuman papillomavirus (HPV) is the
main cause of cervical cancer in women.1,2 Usually, HPV in-
fections are cleared quickly within 1-2 years. Persistence of an
oncogenic HPV infection is the first step towards cervical pre-
cancerous lesions and, more rarely, cervical cancer.3 The pub-
lic health impact of HPV infections is more evident in women;
however, high-risk HPVs are also responsible for other signifi-
cant cancers like ano-genital and head-and-neck cancers, not
necessarily correlated to female gender.4,5 In USA, during
2004-2008, 33,369 HPV-associated cancers (with a rate
amounting to 10.8 cases per 100,000) were notified annually:
12,080 cases were among males (8.1 per 100,000) and 21,290
among females (13.2 per 100,000), according to data from the
National Program of Cancer Registries and the Surveillance,
Epidemiology, and End Results program.6Cervical cancer was
the most frequently notified, with about 11,967 cases per year,
immediately followed by oropharyngeal cancer, with 11,726
cases per year. Furthermore, 2,370 head-and-neck cancers were
registered among females and 9,356 among males. Particularly,
the rate of head-and-neck cancers among males was four times
higher than that among females (6.2 versus 1.4 per 100,000).
Finally, anal cancer was more common among females (1.8 per
100,000) than among males (1.2 per 100,000).6
Two vaccines, the bivalent HPV-16/18 and the quadrivalent
HPV-16/18/6/11, are currently available and recommended for
protection against HPV infection. The main goal of current
vaccination programs is the prevention of cervical cancer in fe-
males by reducing infections and precancerous lesions caused by
high-risk HPV types in naïve girls. A cross-protective efficacy
against four oncogenic non-vaccine HPV types (HPV
33/31/45/51) was reported for the bivalent HPV 16/18 vaccine,
while the quadrivalent HPV 16/18/6/11 vaccine, in addition to
the same cross protection, especially against HPV 33 and 31, also
protects directly against genital warts caused by the low-risk
HPV 6 and 11.7-10
HPV vaccination is usually recommended for 12-year-old girls.
However, in many countries the goal of vaccination coverage
(>70-80%) has not been reached in the target cohorts. In Italy,
vaccination coverage with the complete schedule was 71% for
the 1997-2000 girl cohorts in 2014, with wide regional vari-
ability, and did not show the expected increase in the last invited
cohorts.11HPV vaccination coverage of girls was also lower than
expected in other European countries.12
In order to improve the impact of HPV vaccination (reducing
HPV transmission and, consequently, incidence of infections,
disease, and cancer in females through herd immunity and re-
duction of HPV infections in males), some countries with low
vaccination coverage for the main target population (e.g., USA,
with 49% of adolescent girls with at least the first of three HPV
doses in 2010) have recently extendedHPV vaccination offer to
boys in a universal immunization program.13,14
Universal HPV immunization, including boy cohorts, could de-
termine benefits by direct boys’ immunization, but also by in-
direct protection of unvaccinated girls.
Therefore, while clinical benefits of adding vaccination to boys
has been clearly demonstrated, themost debated issue is the cost-
effectiveness profile of universal vaccination. In the last ECDC
guidance on the introduction of HPV vaccination in European
Union countries, universal HPV immunization programs in-
cluding boys were considered too expensive compared to the po-
tential benefits. This was in accordance with several original
studies and review articles on the economic impact of HPV vac-
cination already published at the time the guidance was issued.12
The aim of the present study was to perform an updated sys-
tematic review on economic studies related to the extension of
HPV vaccination to boys, considering also the more recent in-
dications (like the reduction to a 2-dose vaccination schedule for
subjects aged <14 years) and the reduced vaccine costs.
MATERIALS AND METHODS
Search strategy
A systematic review of economic studies considering HPV vac-
cination and strategies including boys was performed. PubMed
was searched for articles and reviews pertaining to cost-effec-
tiveness evaluation of HPV vaccination.
A search was made for the following headings: «HPV», «boys»,
«vaccination», «economic evaluation», «cost effectiveness»,
«epidemiological impact». Four search strategies were adopted:
■ search strategy 1: «vaccin*» AND («human papillomavirus»
[MeSH]OR «HPV») AND («ICER»OR «cost effectiv*» OR
«economic evaluation» OR «model*») AND («male» OR
«males»OR «boy*»OR «men»)» – only free open access results;
■ search strategy 2: «HPV vaccination AND («economic evalu-
ation» OR «cost effectiveness») AND («male» OR «men» OR
«boys»)»;
■ search strategy 3: «(«HPV vaccination» OR «human papillo-
mavirus vaccine») AND («economic evaluation» OR «cost ef-
fectiveness» OR «pharmacoeconomics» OR «modelling» OR
«cost-utility analysis» OR «incremental cost-effectiveness ratio»
OR «cost-benefit» OR «epidemiological impact» OR «eco-
nomic impact» OR «mathematical model») AND («male»
OR «men» OR «boys»)»;
■ search strategy 4: «HPV vaccination AND («economic evalu-
ation»OR «cost effectiveness» OR «pharmacoeconomics» OR
«modelling» OR «cost-utility analysis» OR «incremental cost-
effectiveness ratio»OR «cost-benefit» OR «epidemiological im-
pact» OR «economic impact» OR «mathematical model»)
AND («male» OR «men» OR «boys») NOT women».
The identified articles were compared in order to exclude du-
plicate studies. Articles were selected if first in the title, then in
the abstract, and finally in the text they evaluated the economic
extension of HPV vaccination to boys. A general research on
Pubmed was also conducted in order to increase the review sen-
sitivity. In addition, a research of published reviews was per-
formed in order to identify other articles and compare their
outcomes. Figure 1 shows the flow diagram of the literature
search.
Inclusion criteria
The economic studies searched for were original articles in Eng-
lish or Italian, published between 2005 and 2015, evaluating the
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cost-effectiveness of the extension of HPV vaccination to boy co-
horts compared with female-only adolescent immunization
(standard target population for vaccination). All articles were as-
sessed for methodological quality and data extraction was per-
formed by 4 reviewers. In case of doubt, the topic was discussed
together by all authors.
Data extraction
A table including the main relevant data of each study (authors,
year of publication, country, period of analysis, mathematical
model used, vaccine, price per dose and schedule, discounted
rate, population, age of vaccination and catch-up, comparator,
clinical outcomes considered, vaccine efficacy, duration of pro-
tection, assumptions on vaccination coverage, screening status,
sensitivity analysis, economic outcomes – cost/QALY, cost/LYG
– and other outcomes and conclusions) was created.
RESULTS
A total of 289 articles were identified: 246 articles were excluded
because inconsistent with the research topic in the title or in the
abstract, and as a consequence of duplicate removal. After as-
sessment of the remaining 43 full-text articles, 11 were eventu-
ally considered suitable for inclusion in the present review be-
cause the other 32 articles did not focus on economic evaluation.
In addition, 11 reviews were identified which allowed for the
identification of three more articles not collected through the ap-
plied search strategies. Finally, another article identified through
general search in PubMed was included. Other two reviews
were found through general search, but no additional articles
were retrieved. A total of 15 original economic studies were ex-
amined (table 1).
All studies were published in the period 2007-2015; most of
them referred to high-income countries (USA, UK, Australia,
etc.), while two articles referred to middle-income countries
(Mexico17 and Brazil16).
The bivalent vaccine was analyzed in three studies16,18,21 while
the quadrivalent vaccine (HPV 6/11/16/18) was analyzed in the
other 12 studies. Age at vaccination ranged from 9 to 26 years,
but immunization was more frequently administrated in the
twelfth year of age. Some studies also considered a program of
catch up for females and/or males aged 12-25 year in addition
to universal vaccination. All studies took into account a three-
dose schedule, except Laprise et al., which also considered a two-
dose schedule.26Vaccine cost ranged between EUR 110-139 and
USD 59-133. Vaccination coverage rate considered in the stud-
ies varied between 20% (Chesson et al.,24 resulting in USD
23,600/QALY) and 90% (Kim et al.,16 resulting in I$
136,910/QALY).
According toWHO recommendations, a health intervention
is considered cost-effective when cost/quality adjusted life
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Figure 1. Flow diagram of the literature search and studies included or excluded in the review.
Figura 1. Diagramma di flusso della ricerca di letteratura e studi inclusi od esclusi nella review.
Total original articles: 15
a general search identified
1 additional article
two reviews were identified through
a general search, but no additional
articles were found
identification of 11 reviews led to the addition
of 3 articles included in these reviews but not collected
in the previous search
removing non-pertinent full text of original articles:
11 articles
removing non-pertinent abstracts: 43 articles
removing duplicate articles: 60 articles
total extracted articles: 101
title pertinent:
15 articles
title pertinent:
35 articles
title pertinent:
31 articles
title pertinent:
20 articles
Search strategy 1
72 articles
Search strategy 1
61 articles
Search strategy 3
84 articles
Search strategy 4
72 articles
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Author year/ Model/ Vaccine used/ Disc. Model Morbidities Vaccination age/ Comparator Vaccine Duration
country period vaccine cost/ rate population catch up efficacy of
of analysis schedule protection
Elbasha 200715 dynamic HPV 6/11/16/18 3% cohort based CIN 2/3 12 y F only 90% lifelong
USA 100 y USD 360 (2005) on US CC, GW no CU or 12-24 y
3 doses population F&M
Kim 200716 dynamic HPV 16/18 3% cohort based age-specific 12 y F only vs F&M 100% lifelong
Brazil n.a. I$ 25-400 (2000) on BrazilIian cancer incidence n.a.
3 doses population rates (HPV16-18
associated only)
Insinga 200717 dynamic HPV 6/11/16/18 3% cohort based CIN 2/3 12 y F only 90% lifelong
Mexico 62 y USD 240 on Mexican CC, GW no or CU 12-24 F only + CU for F
3 doses population for F&M F&M + CU for F
Kulasingam 200718 Markov HPV 16/18 5% cohort based all HPV 16/18 12 y screening only 100% lifelong
Australia n.a. AUD 115/dose (2005) onAustralian associated no
3 doses population diseases
Jit 200819 dynamic HPV 6/11/16/18 3.5% cohorts based CIN, CC, GW 12-25 y F only + CU 100% vs lifelong
UK 100 y GBP 60-80.50/dose on UK HPV-related no 12-25 y vaccine type 10 y
(2006-2007) population HPV infection
3 doses
Kim 200920 hybrid/dynamic HPV 6/11/16/18 3% cohort based all HPV-related 12 y F only vs infection: lifelong
USA n.a. USD 120/dose (2006) on US diseases n.a. F 100%
3 doses population M 85%
vs disease
F 100%
M 90%
Zechmeister 200921 dynamic HPV 16/18 5% cohort based CC, CIN 1/3 12 y F only 90% lifelong
Austria 52 y EUR 100/dose on international no (booster
(2007) epidemiological at 10y)
3 doses data
Olsen 201022 dynamic HPV 6/11/16/18 3% heterosexual CC, CIN 1/3, GW 12 y scenario F+CU to 15 y 100% n.a.
Denmark 62 y EUR 415 (2007) CU for F to 15-26 y vs
3 doses F+CU to 26 y
Elbasha 201023 dynamic HPV 6/11/16/18 3% cohort based CC,ANA,VAG, 9-26 y F only 90% lifelong
USA n.a. USD 400 (2008) on US VUL,PEN, H&N, no
3 doses population CIN 1-3, GW, RRP
Chesson 201124 hybrid HPV 6/11/16/18 3% cohort based GW, CC,VAG, F 12-26 y M 12 y F only F: 95% lifelong
USA 100 y USD 116/dose on USA VUL,ANA, PEN, annual CU increased M: 90%
(2008) population ORPH for F 13-26 y coverage in F
3 doses
Pearson 201425 Markov HPV 6/11/16/18 3% cohort based CIN 1/3, GW, CC, 12 y F only 99% 20 y
New Zealand n.a. USD 59/dose (2011) on New Zealand ANA,VUL, ORPH no
3 doses andAustralia
population
Laprise 201426 dynamic HPV 6/11/16/18 3% cohort based GW, CC,VUL, 9 y F only 2-dose: 90% 2-dose: 10-30 y
Canada 70 y CAD 85/dose on Canadian VAG,ANA, PEN, CU 14 y 3-dose: 95% 3-dose: 20 y-lifelong
(2010) population ORPH
2/3 doses
Burger 201427 dynamic HPV 6/11/16/18 4% cohort based GW, CC,VUL, 12 y F only F: 100% lifelong
Norway lifetime USD 75/dose (2010) on Norwegian VAG,ANA, PEN, n.a. M: 90%
3 doses population ORPH
Bresse 201428 dynamic HPV 6/11/16/18 3% cohort based GW, CC,VUL, 9 y no vaccination F: 76-100% lifelong
Austria 100 y EUR 120/dose (2012) onAustrian VAG,ANA, PEN, no M: 41-96% 20 y
3 doses population ORPH
Olsen 201529 dynamic HPV 6/11/16/18 3% heterosexual GW, CIN, CC, 12 y F only 100% lifelong
Denmark 62 y EUR 417 (2008) ANA,VAG,VUL, n.a.
3 doses PEN, H&N
F: female, M: male; Y: years; CC: cervical cancer; GW: genital warts; VAG;: vaginal cancer; VUL: vulvar cancer; ANA: anal cancer; PEN: penil cancer; H&N: head and neck cancer; ORPH: oropharynx cancer; RRP: re
Table 1. Cost-effectiveness studies on HPV vaccination including boys. / Tabella 1. Studi di costo-efficacia sulla vaccinazione anti-HPV nei maschi.
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Coverage Screening Sensitivity analysis Outcome Other outcomes
status natural vaccine economic cost/QALY and conclusions
history parameters parameters cost/LYG
70% current n.a. one-way one-way Vaccinatiom F&M: dominated Quadrivalent vaccine can substantially reduce
Vaccination F&M + CU 12–24 y for F: USD 41,803 genital warts, CIN, and cervical cancer
ICER of most effective strategy (F&M12+CU F&M):
USD 45,056/QALY
25-90% n.d. multi multi multi The ratio for vaccinating both girls and boys Adding boys to a vaccination programme may not be
variate variate variate increased from I$ 810/LYG to I$8,650/LYG, cost-effective in Brazil, unless the cost per vaccinated
as coverage increased person is well below I$50, coverage in girls is well
below 50% and could not be increased.
70% current one-way one-way one-way Vaccination F&M: dominated compared to F only. The most clinically effective strategy was vaccination
Vaccination F&M+CU for F: incremental of 12-year-old females and males combined
USD 16,663/QALY compared to vaccinating with a temporary female and male 12-24-year-old
F+CU for F catch-up program
Further incremental USD 16,702/QALY if CU for F&M
80% current no one-way one-way AUD 33,644 compared to no vaccination program In a setting with effective screening program,
vaccinating boys is likely to be cost-effective when
the morbidity of the screening program is taken
into account (QALY), but not when only mortality
associated with CC is considered (LYG).
80% current multi one-way multi Incremental GBP 113,846 if 10 years’ vaccine Adding boys is unlikely to be cost-effective, even
variate variate protection is assumed if vaccination results in lifelong protection.This is
Incremental GBP 172,892 if 20 y vaccine protection because at 80% coverage it is likely that most
is assumed HPV 16-18 related CC along with many cases of
Incremental GBP 520,255 if lifetime vaccine GW (in both sexes) will be prevented.Therefore the
protection is assumed additional benefits from vaccination of boys are few.
75% current multi multi multi Indipendently from clinical outcomes considered, Our results suggest that if vaccine coverage and
variate variate variate universal vaccination is not cost-effective efficacy are high among preadolescent girls
(cost/QALY: USD 290,290 - 90,870) (12 years), then including boys in an HPV vaccination
program is unlikely to provide good value
for resources compared vwith vaccinating girls only.
65% biannual one-way one-way one-way The additional vaccination of boys increases Vaccinating boys may not be cost-effective
screening the ICER to EUR 311,000/LYG without reducing the vaccine price.
and EUR 299,000/LYG in a public care
perspective or a societal one, respectively
70% current multi multi multi As scenario (12-year-old F and M vaccination HPV type 6-11-16-18 were estimated to be
variate variate variate at 70% coverage rate) ICER: EUR 18,677/QALY eliminated after 50 years of vaccination.
75% current no one-way one-way USD 25,700 if vaccination protects against Adding quadrivalent vaccination to M 9-26 years
all HPV-6/11/16/18 associated diseases potentially has substantial public health and economic
USD 69,000 if it only protects against diseases benefits. The inclusion of M would further reduce
currently in the vaccine indication HPV-related morbidity and is cost-effective
at commonly cited thresholds.
25-30-75% current multi multi multi The incremental cost per QALY gained was was HPV vaccination of M might potentially be
variate variate variate USD 23,600 in the lower female coverage cost-effective, if F coverage is low and if all
scenario (20% coverage at 12 years) potential health benefits are included. In the
USD 184,300 in the higher female coverage long term, adding M to vaccination reduces
scenario (75% coverage at 12 years) HPV-related CC in the three coverage scenarios.
45-56% / 73% current, no efficacy one-way Vaccination of M to achieve the current coverage for Vaccination of boys was not found to be
but cost and coverage F would not be cost-effective, at USD 61,400/QALY cost-effective, even with very low vaccine
excluded considered as gained compared to the current F-only program or program administration costs. In order
independent An intensified F-only program would give for vaccination of males to become cost-effective
variables USD 17,400/QALY gained in New Zealand, the vaccine would need
Adding M to this program was also notcost-effective to be supplied at very low prices and administration
(USD 128,000/QALY) costs would need to be minimized.
80% current multi multi multi Vaccinating boys with 2 or 3 doses The price for M would need to be reduced by more
variate variate variate was not cost-effective than half to make a 2-dose F&M strategy cost-
(always above USD 100,000/QALY) effective vs 3-dose F-only. Adding M to an HPV
vaccination program would extend benefits to MSM,
who do not benefit from the herd effects of F-only
vaccination.
71% current multi multi multi USD 81,700/QALY considering only cancer for F&M At the anticipated tender price, expanding the HPV
variate variate variate USD 60,100/QALY when considering vaccination program to boys may be cost-effective.
all HPV-related conditions Increasing coverage in F is uniformly more effective
and cost-effective and should be considered a priority.
65% current one-way one-way one-way Cost-effective with base case analysis of Decrease in infections (about -70% in F +M) reducing
EUR 26,701/QALY gained for CC only, HPV 16/18-related cancers in both sexes.An
EUR 15,820/QALY also including VAG,VUL and GW, increase of vaccine coverage among F +M from 65%
EUR 10,033/QALY also consideringANA, PEN, ORPH to 80%would accelerate and increase the reduction
in the prevalence of HPV 16/18-related infections
by 10 and 14 points in F and M, respectively.
85% current: one-way multi multi Vaccination of F and M vs vaccination of F only: Extension of the current HPV program in Denmark
(and 70%) F 23-64 y variate variate ICER: EUR 28,031/QALY (2-dose regimen) to include boys and girls is a cost-effective
every 3-5 y ICER: EUR 41,636/QALY (3-dose regimen) preventive intervention.
ecurrent respiratory papillomatosis; CU catch up; AUD: Australian dollars; CAD: Canadian dollars; EUR: Euros; GBP: British pounds; I$: International dollars; USD: US dollars
year (QALY) is less than 1 out of 3 times the Gross Domes-
tic Product (GDP) per capita and very cost-effective if less
than one GDP per capita. Therefore, the cost-effectiveness
threshold is related to the specific economic background of
each country. Based on this assumption, 8 studies (53%)
considered adding boys to the female vaccination program a
cost-effective intervention, with a cost/QALY ranging from
EUR 10,033 (Bresse et al.,28 assuming a 65% coverage) to
USD 81,700 (Burger et al.,27 assuming a 71% coverage).
Chesson et al. considered adding boys to the vaccination pro-
gram to be cost-effective under some assumptions: universal
vaccination is cost-effective if immunization coverage in girls
is less than 30%, but with a vaccine price of USD 116 per dose
($23,600/QALY).24
On the other hand, 6 studies (40%) indicated that universal
vaccination is not cost-effective. Among these studies, Laprise
et al. showed that a two-dose vaccination series for girls and
boys compared to a three-dose series with girls-only vaccina-
tion would become cost-effective if the vaccine price for boys
were reduced by more than half.26 Zechmeister et al. suggested
that vaccinating boys with 3 doses of bivalent vaccine may not
be cost-effective without reducing the vaccine price (price con-
sidered: EUR 110 per dose) and when the economic evalua-
tion is limited to only direct benefits related to cervical carci-
noma prevention.21 In the analysis performed by Kim et al.,
universal vaccination did not turn out to be cost-effective for
prevention of HPV 16 and 18 related cancers in a limited-
resource setting unless the cost of vaccination is well below
USD 50 and vaccine coverage in girls is well below 50%, with
no possible increase.16 Pearson et al. admitted that vaccination
of boys may become cost-effective only if a very low vaccine
price (about USD 30) and lower program administration
costs are achieved in the future.25 The high vaccination cov-
erage rate for girls (80%) assumed in Jit et al. was bound to
determine the lack of cost-effectiveness of male vaccination.19
Finally, like others, in a study performed by Kim et al. con-
sidering a cost per vaccine dose of USD 120, which is far
higher than the current cost, boys’ vaccination was not eco-
nomically favourable.20
Table 2 shows the 13 reviews identified through the literature
search. The oldest reviews concluded that universal vaccination
was not cost-effective compared to female-only vaccination or
increasing coverage among girls.30-34The most recent reviews,
instead, suggested that adding boys could become cost-effective
in the future if vaccine costs are reduced, if coverage among girls
does not increase, and if all HPV-related disease are taken into
account.12,39,41 These statements are in agreement with the
findings of our review.
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Authors Year Number of evaluated Main conclusions
articles (year range)
Newall et al.30 2007 4 (2003-2004) The additional vaccination of boys was found to be unttractive under most plausible scenarios.
Kim et al.31 2008 6 (2004-2007) Vaccination of boys is unlikely to be cost-effective if reasonable levels of coverage are achieved in girls
Increasing vaccine coverage of girls is always more cost-effective than extending coverage to boys.
Brisson et al.32 2009 12 (2003-2008) If vaccine coverage is high in girls, including boys in a vaccination program will not be cost-effective.
Marra et al.33 2009 13 (2003-2008) The cost effectiveness of a male and female vaccination program is generally not cost-effective
compared with female-only vaccination.
Jeurissen et al.34 2009 11 (2003-2008) Vaccinating boys is not cost-effective.
Garland et al.35 2010 5 (2002-2009) Inclusion of males in an HPV vaccination program is likely to have significant health and economic
benefits. Comprehensive cost–benefit analyses are needed to determine the efficacy of these
programs in the overall population.
Seto et al.36 2012 29 (2007-2010) It appears that the addition of boys to a vaccination program generally exceeds traditional
cost-effectiveness thresholds. The MSM population represents a potential additional target for routine
HPV vaccination.
Low et al.37 2012 18 (2000-2010) Models currently show that vaccination strategies with high female coverage enjoy the same benefits
with greater savings than strategies that include males. Benefits of vaccinating males often do not
warrant the high cost when considering only prevention of cervical cancer. Authors suspect that once
adequate adequate cost-effectiveness modelling of HPV-related morbidities in males is completed,
data will support vaccination in men at that time.
Canfell et al.38 2012 3 (2009-2011) Although the inclusion of males in HPV vaccination programs can be cost-effective in some
circumstances, increasing coverage in males is unlikely to be associated with a more attractive
cost-effectiveness ratio than increasing coverage in females, if this can be achieved.
ECDC12 2012 11 (2004-2011) Universal HPV vaccination may not be cost-effective. The cost-effectiveness can be re-assessed
if vaccination costs are significantly reduced in the future, especially if regimens of less than 3 vaccine
doses are proven to be just as efficacious as the current standard vaccination protocols.
Jiang et al.39 2013 9 (2004-2011) More favourable cost-effectiveness appeared when all HPV-related disease outcomes were considered,
a suboptimal vaccine coverage among girls, and/or lower vaccine prices were assumed.
Fasenfeld et al.40 2013 25 (2007-2012) Two study considering vaccination in males, contrasting conclusions due to different assumptions
(GW included, higher threshold and lower vaccine efficacy in the favourable study).
Marsh et al.41 2014 8 (2004-2011) Current studies of the cost-effectiveness of universal HPV vaccination suffer from a number
of limitations. Decisions to invest in universal HPV vaccination need to be based on a complete
assessment of the value that it generates. This is not provided by existing economic evaluations.
Table 2. Reviews of cost-effectiveness studies on HPV vaccination including boys. / Tabella 2. Review di studi di costo-efficacia sulla vaccinazione anti-HPV nei maschi.
DISCUSSION AND CONCLUSIONS
The previous published reviews showed that the cost-effective-
ness of universal vaccination with the old parameters was con-
troversial and generally unfavourable.
The results of this review, instead, show that many studies
have a favourable cost-effectiveness profile, while others indicate
that it could be cost-effective only with a low vaccination cov-
erage in girls and with lower vaccine costs. However, in the last
years, vaccine cost has decreased greatly worldwide compared
to the price assumed in the analyzed studies. For example, the
current cost per dose is about EUR 35 in Italy: this parameter
surely has a great effect on the total costs of a universal vacci-
nation program. In addition, the European Medicine Agency
(EMA) authorized a two-dose schedule for both vaccines when
used in younger subjects (≤13 and ≤14 years for the quadriva-
lent and bivalent vaccines, respectively).42 Indeed, considering
the input parameters in studies not favourable to universal
vaccination, and their conclusions, at the current price of EUR
35 per dose and a two-dose schedule instead of a three-dose reg-
imen, results would become cost-effective in all studies (Laprise
et al.,26 Zechmeister et al.,21 Jit et al.,19 Kim et al.20), except
Kim et al.16 and Pearson et al.,25 whose conclusions would re-
main unfavourable to universal adolescent vaccination strategy.
If Chesson et al.24 had considered a price per dose of USD
38.11 (about EUR 35) instead of 116, and a two-dose regimen,
their conclusions would have been favourable, too. In the other
studies, with updated parameters, the results would be even
more favourable for universal vaccination. These two parame-
ters (price and number of doses) are a crucial change for the eco-
nomic sustainability of universal vaccination. Therefore, eco-
nomic studies should be updated assuming more recent
vaccination costs and immunization schedules, so that the cost-
effectiveness profile of universal vaccination would most likely
be significantly improved.
In addition, as reported by Marsh et al.,41 all HPV-related
clinical outcomes should be included in economic studies in or-
der to obtain a more accurate cost-effectiveness profile. Lastly,
new economic evaluation onHPV universal vaccination should
also be performed considering the availability of a 9-valent
HPV vaccine in the near future.
Therefore, many issues are still open and should be further an-
alyzed. For example, no evaluation on universal immunization
policies is available for the scenario where vaccine coverage is
70% (a value that Kim et al.31 recognize as insufficient). How-
ever, compared to previous reviews, our findings show better re-
sults in the economic evaluation of adding boys to vaccination,
especially with updated economic parameters (12 studies out of
15 would confirm cost-effectiveness).
A possible limitation of our review is the use of a single electronic
database (PubMed).We cannot rule out the possibility that a few
articles on the subject may have been missed.
In conclusion, a universal HPV vaccination program could
greatly reduce the incidence of new HPV infections in the
population, and is likely to be cost-effective and economically
sustainable, considering current vaccine prices and the two-dose
schedule. Taking into account that several recent epidemiolog-
ical studies and reviews have highlighted that HPV-related dis-
eases pose a substantial burden even on males, the extension of
HPV vaccination to boys is highly desirable and should become
a reality in many countries in the next few years
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